2020

1. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

   The Lancet Child and Adolescent Health, Vol. 4, Núm. 10, pp. 728-739